CYRX Stock - Cryoport, Inc.
Unlock GoAI Insights for CYRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $233.25M | $237.28M | $222.61M | $222.61M | $78.70M |
| Gross Profit | $99.33M | $103.87M | $96.58M | $96.58M | $36.33M |
| Gross Margin | 42.6% | 43.8% | 43.4% | 43.4% | 46.2% |
| Operating Income | $-115,157,000 | $-31,904,000 | $-17,829,000 | $-17,829,000 | $-30,010,000 |
| Net Income | $-99,587,000 | $-37,333,000 | $-275,528,000 | $-275,528,000 | $-32,693,000 |
| Net Margin | -42.7% | -15.7% | -123.8% | -123.8% | -41.5% |
| EPS | $-2.21 | $-0.93 | $-6.18 | $-6.18 | $-1.94 |
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 6th 2025 | KeyBanc Capital Markets | Upgrade | Overweight | - |
| August 6th 2025 | Leerink Partners | Upgrade | Outperform | $16 |
| July 22nd 2025 | Stephens | Resumed | Overweight | $13 |
| March 24th 2025 | UBS | Upgrade | Buy | $10 |
| December 19th 2024 | Guggenheim | Initiation | Buy | $11 |
| August 7th 2024 | Jefferies | Downgrade | Hold | $8← $20 |
| July 31st 2024 | B. Riley Securities | Upgrade | Buy | $15← $19 |
| May 3rd 2024 | B. Riley Securities | Downgrade | Neutral | $19← $22 |
| April 4th 2024 | Jefferies | Resumed | Buy | $21← $17 |
| March 13th 2024 | Needham | Reiterated | Buy | $18← $19 |
| August 17th 2023 | Morgan Stanley | Initiation | Equal Weight | $16 |
| August 10th 2023 | Stephens | Downgrade | Equal Weight | $15 |
| July 18th 2023 | UBS | Downgrade | Neutral | $17← $28 |
| July 17th 2023 | KeyBanc Capital Markets | Downgrade | Sector Weight | - |
| July 13th 2023 | SVB Securities | Downgrade | Market Perform | $10← $30 |
Earnings History & Surprises
CYRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.23 | $-0.18 | +21.7% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.20 | $-0.29 | -45.0% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q1 2025 | Mar 4, 2025 | $-0.33 | $-0.42 | -27.3% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.29 | $-0.02 | +93.1% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.37 | $-0.33 | +10.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.35 | $-0.43 | -22.9% | ✗ MISS |
Q1 2024 | Mar 12, 2024 | $-0.32 | $-0.51 | -59.4% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.30 | $-0.31 | -3.3% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.24 | $-0.42 | -75.0% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.19 | $-0.24 | -26.3% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.15 | $-0.17 | -13.3% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.20 | $-0.31 | -55.0% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.15 | $-1.32 | -780.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.14 | $-0.18 | -28.6% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.12 | $-0.16 | -33.3% | ✗ MISS |
Latest News
UBS Maintains Buy on CryoPort, Raises Price Target to $12.5
📈 PositiveNeedham Maintains Buy on CryoPort, Raises Price Target to $12
📈 PositiveCryoPort Raises FY2025 Sales Guidance from $165.000M-$172.000M to $170.000M-$174.000M vs $171.035M Est
📈 PositiveCryoPort Q3 Adj. EPS $(0.18) Beats $(0.21) Estimate, Sales $44.233M Beat $41.356M Estimate
📈 PositiveCryoport's Cryoport Systems Achieves ISO 21973:2020 Certification, The International Standard For Transporting Human Cells For Therapeutic Use
📈 PositiveBTIG Maintains Buy on CryoPort, Raises Price Target to $15
📈 PositiveFrequently Asked Questions about CYRX
What is CYRX's current stock price?
What is the analyst price target for CYRX?
What sector is Cryoport, Inc. in?
What is CYRX's market cap?
Does CYRX pay dividends?
Similar Stocks
Industrials SectorExplore stocks similar to CYRX for comparison